Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Acquire Antibody Maker Zymed for $60M

NEW YORK, Jan. 10 (GenomeWeb News) - Invitrogen plans to acquire antibody manufacturer Zymed Laboratories for $60 million in cash, the company said today.

 

Zymed, based in South San Francisco, offers immunoassay reagents for research and clinical diagnostics. The company has more than 2,000 antibodies and related products suitable for research in the areas of cancer, neurological diseases, and infectious disease.

 

Following the acquisition, which is expected to close by the end of February, Zymed's South San Franciscofacility will become the main site for Invitrogen's antibody production and distribution.

 

Invitrogen expects Zymed to generate $15 million in sales during the first year following the acquisition.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.